Search
Back

Afatinib Dimaleate

CAS 850140-73-7
Afatinib Dimaleate

General Information

Afatinib dimaleate, the dimaleate salt form of afanitib, is an orally available antineoplastic agent. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. In the past, standard treatment with a platinum-based chemotherapy doublet regimen was considered standard first-line therapy for all patients with NSCLC. However, emerging evidence has identified subpopulations in which targeted therapy is more effective, leading to the development of mutation-specific drugs.


About the API

Technology Synthetic
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

Updates About Afatinib Dimaleate

March 28, 2017
New DMF is now available for reference on the FDA website.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.